TUSTIN, Calif., March 22, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has been named a recipient of six 2018 Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers with the industry’s highest level of service. Now in its 7th year, Life Science Leader’s CMO Leadership Awards aim to provide industry insiders with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.
Avid received awards in the following categories:
- Quality
- Reliability
- Capabilities
- Expertise
- Compatibility
- Service
“We believe that one of the greatest competitive differentiators helping to drive the growth of Avid’s CDMO business is the company’s long-standing reputation for excellence within the industry. With the CMO Leadership Award winners selected, in part, based on surveys of customers of CDMO services, our receipt of six awards highlights the meaningful impact our focus on quality, reliability, capabilities, expertise, compatibility and service is having on industry sentiment,” said Roger Lias, Ph.D., president and chief executive officer of Avid Bioservices. “We’d like to take this opportunity to thank all of our employees who strive for excellence every day, as well as those individuals who championed Avid as being worthy of each of the CMO awards we received.”
For more information about Life Science Leader’s CMO Leadership Awards, please visit: http://cmoleadershipawards.com/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]


OpenAI Nears Astra AI Model Launch With Safety Focus
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips
OpenAI Rejects Apple Trade Secret Theft Claims
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment
GM Canada Workers Approve C$1.1 Billion Investment Deal
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates
Street Poller Media and The Boom of the Street Interview Ad Industry
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR
Amazon Secures 200 MW Wind Power Deals in Sweden
Faraday Future Delivers First Robots in Middle East, Plans September Launches
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns
Shein Shares Drop 5% After Weak Hong Kong IPO Debut
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 



